In summary, our findings are important to develop new combination treatments for HNSCC that involve targeting PVT1 to eliminate CSCs, prevent metastasis, and activate the intrinsic immune responses of tumor cells. The gene discussed is PVT1; the disease is head and neck squamous cell carcinoma.